[8-K] NRX Pharmaceuticals, Inc. Reports Material Event
NRx Pharmaceuticals reported that it recently raised an aggregate of approximately $8.8 million in gross proceeds from sales of common stock. The company clarified that this amount is comprised of gross proceeds from a registered direct common stock offering announced in August 2025 and from shares sold under its at-the-market (ATM) offering since the current fiscal quarter began on July 1, 2025. The company said these issuances included no warrants, repricing adjustments, or other variable rate features, and that the substantial majority of the proceeds were placed with experienced biotech investors. The disclosure notes the company will revert to reporting ATM gross proceeds in its quarterly reports and furnishes a related press release as an exhibit.
NRx Pharmaceuticals ha comunicato di aver recentemente raccolto complessivamente circa 8,8 milioni di dollari in proventi lordi dalla vendita di azioni ordinarie. La società ha precisato che questa somma comprende i proventi lordi di un'offerta diretta registrata di azioni ordinarie annunciata nell'agosto 2025 e le azioni vendute tramite il suo programma at-the-market (ATM) dall'inizio del corrente trimestre fiscale, il 1° luglio 2025. NRx ha affermato che tali emissioni non includevano warrant, aggiustamenti di repricing o altre caratteristiche a tasso variabile, e che la quota prevalente dei proventi è stata sottoscritta da investitori biotech esperti. La nota informa inoltre che la società riprenderà a riportare i proventi lordi ATM nei suoi report trimestrali e allega un comunicato stampa correlato come exhibit.
NRx Pharmaceuticals informó que recientemente recaudó un total aproximado de 8,8 millones de dólares en ingresos brutos por la venta de acciones ordinarias. La compañía aclaró que esa cifra incluye los ingresos brutos de una oferta registrada directa de acciones ordinarias anunciada en agosto de 2025 y las acciones vendidas a través de su programa at-the-market (ATM) desde el inicio del trimestre fiscal actual, el 1 de julio de 2025. La empresa indicó que estas emisiones no incluían warrants, ajustes de repricing u otras características de tasa variable, y que la gran mayoría de los ingresos se colocaron entre inversores biotecnológicos experimentados. La divulgación señala además que la compañía volverá a informar los ingresos brutos del ATM en sus informes trimestrales y adjunta un comunicado de prensa relacionado como exhibit.
NRx Pharmaceuticals는 최근 보통주 판매로 약 880만 달러의 총수익을 모금했다고 보고했습니다. 회사는 이 금액이 2025년 8월에 발표된 등록 직접 공모(registered direct) 보통주 매각에서의 총수익과 2025년 7월 1일 시작된 현 회계분기부터의 ATM(at-the-market) 제공을 통한 매각분으로 구성되어 있다고 설명했습니다. 회사는 이러한 발행에 워런트, 리프라이싱 조정 또는 기타 변동 금리 특성이 포함되지 않았으며, 수익의 대부분은 경험 있는 바이오테크 투자자들에게 배분되었다고 밝혔습니다. 공시문은 회사가 분기 보고서에서 ATM 총수익 보고로 복귀할 것임을 알리며 관련 보도자료를 전시물(exhibit)로 첨부한다고 덧붙였습니다.
NRx Pharmaceuticals a indiqué avoir récemment levé environ 8,8 millions de dollars de produits bruts issus de la vente d'actions ordinaires. La société a précisé que ce montant comprend les produits bruts d'une offre directe enregistrée d'actions ordinaires annoncée en août 2025 ainsi que des actions vendues dans le cadre de son programme at-the-market (ATM) depuis le début du trimestre fiscal en cours, le 1er juillet 2025. La société a déclaré que ces émissions n'incluaient ni bons de souscription (warrants), ni ajustements de repricing, ni autres caractéristiques à taux variable, et que la grande majorité des produits avait été placée auprès d'investisseurs biotech expérimentés. La communication indique en outre que la société reprendra la déclaration des produits bruts ATM dans ses rapports trimestriels et annexera un communiqué de presse à titre d'exhibit.
NRx Pharmaceuticals meldete, dass es kürzlich insgesamt rund 8,8 Millionen US-Dollar an Bruttoerlösen aus dem Verkauf von Stammaktien erzielt hat. Das Unternehmen stellte klar, dass dieser Betrag die Bruttoerlöse aus einem im August 2025 angekündigten registrierten Direktangebot von Stammaktien sowie aus seit Beginn des laufenden Geschäftsdrittels am 1. Juli 2025 über sein At-the-Market-(ATM)-Programm verkauften Aktien umfasst. NRx erklärte, diese Emissionen enthielten keine Warrants, Repricing-Anpassungen oder sonstige variabel verzinsliche Merkmale und dass der überwiegende Teil der Erlöse bei erfahrenen Biotech-Investoren platziert wurde. Die Offenlegung weist zudem darauf hin, dass das Unternehmen in seinen Quartalsberichten wieder ATM-Bruttoerlöse ausweisen wird und ein dazugehöriges Pressemitteilungsexhibit beifügt.
- Approximately $8.8 million in gross proceeds were raised through common stock sales
- Proceeds are comprised of a registered direct offering and ATM program, providing capital via two established channels
- No warrants, repricing adjustments, or other variable rate features were included, simplifying dilution assessment
- The substantial majority of the proceeds were placed with experienced biotech investors
- Company will resume reporting ATM gross proceeds in its quarterly reports, improving disclosure cadence
- None.
Insights
TL;DR The company raised about $8.8M via direct and ATM equity sales, with no attached warrants or variable features, easing dilution complexity.
The disclosure clarifies the composition of recent equity raises as gross proceeds from a registered direct offering and the companys ATM program, and stresses the absence of warrants or repricing features that might complicate future dilution calculations. Reporting that the majority of shares were placed with experienced biotech investors may indicate investor interest from sector-specialists. The company also states it will resume reporting ATM proceeds in its quarterly filings, which restores routine disclosure cadence for investors.
TL;DR A modest equity raise of ~ $8.8M was completed with straightforward terms; disclosure improves transparency on capital-raising activity.
From a capital-structure perspective, the raise is described as gross proceeds from common stock sales without attached warrants or variable-rate features, which simplifies immediate share-count and dilution analysis. The mix of a registered direct offering and ATM sales is a common approach to balance committed placements with ongoing liquidity-based sales. The return to reporting ATM proceeds in quarterly reports enhances ongoing transparency into incremental equity issuance.
NRx Pharmaceuticals ha comunicato di aver recentemente raccolto complessivamente circa 8,8 milioni di dollari in proventi lordi dalla vendita di azioni ordinarie. La società ha precisato che questa somma comprende i proventi lordi di un'offerta diretta registrata di azioni ordinarie annunciata nell'agosto 2025 e le azioni vendute tramite il suo programma at-the-market (ATM) dall'inizio del corrente trimestre fiscale, il 1° luglio 2025. NRx ha affermato che tali emissioni non includevano warrant, aggiustamenti di repricing o altre caratteristiche a tasso variabile, e che la quota prevalente dei proventi è stata sottoscritta da investitori biotech esperti. La nota informa inoltre che la società riprenderà a riportare i proventi lordi ATM nei suoi report trimestrali e allega un comunicato stampa correlato come exhibit.
NRx Pharmaceuticals informó que recientemente recaudó un total aproximado de 8,8 millones de dólares en ingresos brutos por la venta de acciones ordinarias. La compañía aclaró que esa cifra incluye los ingresos brutos de una oferta registrada directa de acciones ordinarias anunciada en agosto de 2025 y las acciones vendidas a través de su programa at-the-market (ATM) desde el inicio del trimestre fiscal actual, el 1 de julio de 2025. La empresa indicó que estas emisiones no incluían warrants, ajustes de repricing u otras características de tasa variable, y que la gran mayoría de los ingresos se colocaron entre inversores biotecnológicos experimentados. La divulgación señala además que la compañía volverá a informar los ingresos brutos del ATM en sus informes trimestrales y adjunta un comunicado de prensa relacionado como exhibit.
NRx Pharmaceuticals는 최근 보통주 판매로 약 880만 달러의 총수익을 모금했다고 보고했습니다. 회사는 이 금액이 2025년 8월에 발표된 등록 직접 공모(registered direct) 보통주 매각에서의 총수익과 2025년 7월 1일 시작된 현 회계분기부터의 ATM(at-the-market) 제공을 통한 매각분으로 구성되어 있다고 설명했습니다. 회사는 이러한 발행에 워런트, 리프라이싱 조정 또는 기타 변동 금리 특성이 포함되지 않았으며, 수익의 대부분은 경험 있는 바이오테크 투자자들에게 배분되었다고 밝혔습니다. 공시문은 회사가 분기 보고서에서 ATM 총수익 보고로 복귀할 것임을 알리며 관련 보도자료를 전시물(exhibit)로 첨부한다고 덧붙였습니다.
NRx Pharmaceuticals a indiqué avoir récemment levé environ 8,8 millions de dollars de produits bruts issus de la vente d'actions ordinaires. La société a précisé que ce montant comprend les produits bruts d'une offre directe enregistrée d'actions ordinaires annoncée en août 2025 ainsi que des actions vendues dans le cadre de son programme at-the-market (ATM) depuis le début du trimestre fiscal en cours, le 1er juillet 2025. La société a déclaré que ces émissions n'incluaient ni bons de souscription (warrants), ni ajustements de repricing, ni autres caractéristiques à taux variable, et que la grande majorité des produits avait été placée auprès d'investisseurs biotech expérimentés. La communication indique en outre que la société reprendra la déclaration des produits bruts ATM dans ses rapports trimestriels et annexera un communiqué de presse à titre d'exhibit.
NRx Pharmaceuticals meldete, dass es kürzlich insgesamt rund 8,8 Millionen US-Dollar an Bruttoerlösen aus dem Verkauf von Stammaktien erzielt hat. Das Unternehmen stellte klar, dass dieser Betrag die Bruttoerlöse aus einem im August 2025 angekündigten registrierten Direktangebot von Stammaktien sowie aus seit Beginn des laufenden Geschäftsdrittels am 1. Juli 2025 über sein At-the-Market-(ATM)-Programm verkauften Aktien umfasst. NRx erklärte, diese Emissionen enthielten keine Warrants, Repricing-Anpassungen oder sonstige variabel verzinsliche Merkmale und dass der überwiegende Teil der Erlöse bei erfahrenen Biotech-Investoren platziert wurde. Die Offenlegung weist zudem darauf hin, dass das Unternehmen in seinen Quartalsberichten wieder ATM-Bruttoerlöse ausweisen wird und ein dazugehöriges Pressemitteilungsexhibit beifügt.
FAQ
How much capital did NRXP raise and in what form?
Were any warrants or repricing features attached to the stock sales?
Who purchased the majority of the shares in the recent raises?
How will NRXP report future ATM proceeds?
Does the filing include the press release about the capital raise?
